Peninsula biotech looks to turn once-failed osteoporosis drug against rare disease
A Bay Area company went on the hunt for a certain class of drugs that could level off calcium levels in both the blood and urine. Now it plans to take a drug into a late-stage clinical trial for people at risk of deadly kidney disease.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Biotechnology | Calcium | Clinical Trials | Health Management | Orthopaedics | Osteoporosis | Rare Diseases | Urology & Nephrology